Epcoritamab,rituximab,cyclophosphamide,doxorubicin,vincristine,prednisone,lenalidomide,bendamustine,cytarabine,dexamethasone,oxaliplatin,carboplatin,gemcitabine,ifosfamide
genmab,abbvie
['epco ', 'lymsm', 'dlbcl']
epco + r-chop in 1l high-risk dlbcl #17icml:
- epco during r-chop x 6 then maint for 1 yr
- 46 pts (11 dhl/thl)
- cr &gt;80% (!!!), including across high-risk groups (dhl/thl, high ipi)
- 1 pt with high-grade crs
- mpfs nr (see curve), high dor
impressive data for dhl/thl. #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈